secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2024-07-01T23:59:59+00:00
Accession:  0001372514-24-000068
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora appoints Walters-Hoffert to board, promotes Tosca to CFO, regains Nasdaq compliance
--------------------------------------------------------------------------------

- Lisa Walters-Hoffert appointed independent director and audit committee chair; Kenneth Gayron resigned.
- Melissa Tosca promoted from EVP of Finance to CFO; salary raised to $337,000, bonus target to 40%.
- CEO Brian Strem's salary increased to $569,000 (55% bonus); Chief Development Officer Daniels to $443,000 (40%).
- New non-employee director compensation: initial 1,778 stock option grant, cash retainers up to $70,000 annually.
- Regained compliance with Nasdaq minimum bid price rule (Nasdaq Listing Rule 5550(a)(2)) as of June 28, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251424000068/0001372514-24-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251424000068/kprx-20240628.htm
  HTML page:      https://secwatch.observer/filing/0001372514-24-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer